プレスリリース
前のページへ戻る
 


News Release
August 29, 2017
Your Contact:
Karen Tiano +49 6151 72 44461

Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy
  • Project is first for Merck’s Massachusetts BioReliance® End-to-End Solutions center
  • Collaboration gives Angiex access to Merck’s process development tools and technologies

Darmstadt, Germany, August 9, 2017 Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up’s ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

The collaboration with Angiex is the first project to be undertaken at Merck’s new biodevelopment center in Massachusetts, USA. Merck will give Angiex access to end-to-end process development tools, education programs and training to support its success.

“Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer for companies like Angiex.”

Angiex CEO Dr. Paul Jaminet applauded Merck’s broad range of process development capabilities and services for customers at all stages of molecule development and commercialization. “Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate Merck’s expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors,” Jaminet said.

Merck’s BioReliance® End-to-End Solutions deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance® End-to-End Solutions, Merck will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.

Merck’s BioReliance® End-to-End Solutions is part of the Process Solutions business area within the Life Science business of Merck.

About Angiex

Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex is resident at LabCentral in Cambridge, Massachusetts.

メルクについて
Merck(メルク)はヘルスケア、ライフサイエンス、パフォーマンスマテリアルズの分野における世界有数のサイエンスとテクノロジー企業です。がんや多発性硬化症のためのバイオ医薬品を用いた治療法から、科学研究と生産に関する最先端システム、スマートフォンや液晶テレビ向けの液晶材料にいたるまで、約53,000人の従業員が人々の暮らしをより良くする技術の一層の進歩を目指しています。2017年は66カ国で153億ユーロの売上高を計上しました。

メルクは1668年に創業された世界で最も歴史の長い医薬・化学品会社で、 創業家が今でも、上場企業が率いるメルクグループの株式の過半数を所有しています。メルクの名称およびブランドのグローバルな権利は、メルクが保有しています。唯一の例外は米国とカナダで、両国ではEMDセローノ、ミリポアシグマ、EMDパフォーマンスマテリアルズとして事業を行っています。